Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Musculoskeletal Disorders
Published in: BMC Musculoskeletal Disorders 1/2010

Open Access 01-12-2010 | Research article

Myositis autoantibodies in Korean patients with inflammatory myositis: Anti-140-kDa polypeptide antibody is primarily associated with rapidly progressive interstitial lung disease independent of clinically amyopathic dermatomyositis

Authors: Eun Ha Kang, Ran Nakashima, Tsuneyo Mimori, Jinhyun Kim, Yun Jong Lee, Eun Bong Lee, Yeong Wook Song

Published in: BMC Musculoskeletal Disorders | Issue 1/2010

Login to get access

Abstract

Background

To investigate the association between myositis autoantibodies and clinical subsets of inflammatory myositis in Korean patients.

Methods

Immunoprecipitation was performed using the sera of classic polymyositis (PM) (n = 11) and dermatomyositis (DM) (n = 38) patients who met the Bohan and Peter criteria for definite inflammatory myositis. A panel of defined myositis autoantibodies was surveyed to investigate the association between each autoantibody and clinical subsets of inflammatory myositis.

Results

Either MSAs, anti-p140, or anti-p155/140 antibodies were found in 63.3% (31/49) of the study subjects. Anti-140-kDa-polypeptide (anti-p140) (18.4%, 9/49) and anti-155/140-kDa polypeptide (anti-p155/140) (16.3%, 8/49) antibodies were the most common, followed by anti-Mi2 (14.3%, 7/49), anti-ARS (12.2%, 6/49) and anti-SRP (2.0%, 1/49) antibodies. All MSAs and anti-p140 and anti-p155/140 antibodies were mutually exclusive. Anti-p140 (23.7%, 9/38), anti-p155/140 (21.1%, 8/38), and anti-Mi2 (18.4%, 3/38) antibodies were found exclusively in DM patients. Anti-p140 antibody was associated with rapidly progressive interstitial lung disease (ILD) (p = 0.001), with a sensitivity of 100.0% (4/4) and a specificity of 85.3% (29/34) in DM patients. Anti-p155/140 antibody was associated with cancer-associated DM (p = 0.009), with a sensitivity of 55.6% (5/9) and a specificity of 89.7% (26/29). Cancer-associated survival was significantly worse when anti-p155/140 antibody was present (19.2 ± 7.6 vs. 65.0 ± 3.5 months, p = 0.032). Finally, anti-ARS antibodies were associated with stable or slowly progressive ILD in PM and DM patients (p = 0.005).

Conclusions

Anti-p140 and anti-p155/140 antibodies were commonly found autoantibodies in Korean patients with inflammatory myositis. Despite the lack of clinically amyopathic DM patients in the study subjects, a strong association was observed between anti-p140 antibody and rapidly progressive ILD. Anti-p155/140 antibody was associated with cancer-associated myositis and poor survival.
Appendix
Available only for authorised users
Literature
1.
Nagaraju K, Plotz PH, Miller FW: Etiology and pathogenesis of inflammatory muscle disease. Rheumatology. Edited by: Hochberg MC, Silman AJ, Smolen JS, Weinblatt ME, Weisman MH. 2003, New York: Mosby, 2: 1523-1536. 3
2.
Marie I, Hachulla E, Chérin P, Dominique S, Hatron PY, Hellot MF, Devulder B, Herson S, Levesque H, Courtois H: Interstitial lung disease in polymyositis and dermatomyositis. Arthritis Rheum. 2002, 47: 614-622. 10.1002/art.10794.CrossRefPubMed
3.
Marie I, Hachulla E, Hatron PY, Hellot MF, Levesque H, Devulder B, Courtois H: Polymyositis and dermatomyositis: short term and longterm outcome, and predictive factors of prognosis. J Rheumatol. 2001, 28: 2230-2237.PubMed
4.
Euwer RL, Sontheimer RD: Amyopathic dermatomyositis (dermatomyositis siné myositis). Presentation of six new cases and review of the literature. J Am Acad Dermatol. 1991, 24: 959-966. 10.1016/0190-9622(91)70153-S.CrossRefPubMed
5.
Gerami P, Schope JM, McDonald L, Walling HW, Sontheimer RD: Systematic review of adult-onset clinically amyopathic dermatomyositis (dermatomyositis siné myositis): a missing link within the spectrum of the idiopathic inflammatory myopathies. J Am Acad Dermatol. 2006, 54: 597-561. 10.1016/j.jaad.2005.10.041.CrossRefPubMed
6.
Ozawa Y, Kurosaka D, Yokoyama T, Tajima N: Therapeutic efficacy of cyclosporin A in four cases of amyopathic dermatomyositis with rapidly progressive interstitial pneumonia. Ryumachi. 2000, 40: 798-809.PubMed
7.
Kang EH, Lee EB, Shin KC, Im CH, Chung DH, Han SK, Song YW: Interstitial lung disease in patients with polymyositis, dermatomyositis and amyopathic dermatomyositis. Rheumatology (Oxford). 2005, 44: 1282-1286. 10.1093/rheumatology/keh723.CrossRef
8.
Love LA, Leff RL, Fraser DD, Targoff IN, Dalakas M, Plotz PH, Miller FW: A new approach to the classification of idiopathic inflammatory myopathy: myositis-specific autoantibodies define useful homogeneous patient groups. Medicine (Baltimore). 1991, 70: 360-374.CrossRef
9.
Sato S, Hirakata M, Kuwana M, Suwa A, Inada S, Mimori T, Nishikawa T, Oddis CV, Ikeda Y: Autoantibodies to a 140-kd polypeptide, CADM-140, in Japanese patients with clinically amyopathic dermatomyositis. Arthritis Rheum. 2005, 52: 1571-1576. 10.1002/art.21023.CrossRefPubMed
10.
Kaji K, Fujimoto M, Hasegawa M, Kondo M, Saito Y, Komura K, Matsushita T, Orito H, Hamaguchi Y, Yanaba K, Itoh M, Asano Y, Seishima M, Ogawa F, Sato S, Takehara K: Identification of a novel autoantibody reactive with 155 and 140 kDa nuclear proteins in patients with dermatomyositis: an association with malignancy. Rheumatology (Oxford). 2007, 46: 25-28. 10.1093/rheumatology/kel161.CrossRef
11.
Targoff IN, Mamyrova G, Trieu EP, Perurena O, Koneru B, O'Hanlon TP, Miller FW, Rider LG, Childhood Myositis Heterogeneity Study Group; International Myositis Collaborative Study Group: A novel autoantibody to a 155-kd protein is associated with dermatomyositis. Arthritis Rheum. 2006, 54: 3682-3689. 10.1002/art.22164.CrossRefPubMed
12.
Fujikawa K, Kawakami A, Kaji K, Fujimoto M, Kawashiri S, Iwamoto N, Aramaki T, Ichinose K, Tamai M, Kamachi M, Nakamura H, Ida H, Origuchi T, Ishimoto H, Mukae H, Kuwana M, Kohno S, Takehara K, Sato S, Eguchi K: Association of distinct clinical subsets with myositis-specific autoantibodies towards anti-155/140-kDa polypeptides, anti-140-kDa polypeptides, and anti-aminoacyl tRNA synthetases in Japanese patients with dermatomyositis: a single-centre, cross-sectional study. Scand J Rheumatol. 2009, 38: 263-267. 10.1080/03009740802687455.CrossRefPubMed
13.
Nakashima R, Imura Y, Kobayashi S, Yukawa N, Yoshifuji H, Nojima T, Kawabata D, Ohmura K, Usui T, Fujii T, Okawa K, Mimori T: The RIG-I-like receptor IFIH1/MDA5 is a dermatomyositis-specific autoantigen identified by the anti-CADM-140 antibody. Rheumatology (Oxford). 2010, 49: 433-440. 10.1093/rheumatology/kep375.CrossRef
14.
Chinoy H, Fertig N, Oddis CV, Ollier WE, Cooper RG: The diagnostic utility of myositis autoantibody testing for predicting the risk of cancer-associated myositis. Ann Rheum Dis. 2007, 66: 1345-1349. 10.1136/ard.2006.068502.CrossRefPubMedPubMedCentral
15.
Trallero-Araguás E, Labrador-Horrillo M, Selva-O'Callaghan A, Martínez MA, Martínez-Gómez X, Palou E, Rodriguez-Sanchez JL, Vilardell-Tarrés M: Cancer-associated myositis and anti-p155 autoantibody in a series of 85 patients with idiopathic inflammatory myopathy. Medicine (Baltimore). 2010, 89: 47-52. 10.1097/MD.0b013e3181ca14ff.CrossRef
16.
Gunawardena H, Wedderburn LR, North J, Betteridge Z, Dunphy J, Chinoy H, Davidson JE, Cooper RG, McHugh NJ, Juvenile Dermatomyositis Research Group UK: Clinical associations of autoantibodies to a p155/140 kDa doublet protein in juvenile dermatomyositis. Rheumatology (Oxford). 2008, 47: 324-328. 10.1093/rheumatology/kem359.CrossRef
17.
Chinoy H, Salway F, John S, Fertig N, Tait BD, Oddis CV, Ollier WE, Cooper RG, UK Adult Onset Myositis Immunogenetic Collaboration (AOMIC): In adult onset myositis, the presence of interstitial lung disease and myositis specific/associated antibodies are governed by HLA class II haplotype, rather than by myositis subtype. Arthritis Res Ther. 2006, 8: R13-10.1186/ar1862.CrossRefPubMed
18.
O'Hanlon TP, Carrick DM, Targoff IN, Arnett FC, Reveille JD, Carrington M, Gao X, Oddis CV, Morel PA, Malley JD, Malley K, Shamim EA, Rider LG, Chanock SJ, Foster CB, Bunch T, Blackshear PJ, Plotz PH, Love LA, Miller FW: Immunogenetic risk and protective factors for the idiopathic inflammatory myopathies: distinct HLA-A, -B, -Cw, -DRB1, and -DQA1 allelic profiles distinguish European American patients with different myositis autoantibodies. Medicine (Baltimore). 2006, 85: 111-127. 10.1097/01.md.0000217525.82287.eb.CrossRef
19.
Bohan A, Peter JB: Polymyositis and dermatomyositis (first of two parts). N Engl J Med. 1975, 292: 344-347. 10.1056/NEJM197502132920706.CrossRefPubMed
20.
Rider LG, Shamim E, Okada S, Pandey JP, Targoff IN, O'Hanlon TP, Kim HA, Lim YS, Han H, Song YW, Miller FW: Genetic risk and protective factors for idiopathic inflammatory myopathy in Koreans and American whites: a tale of two loci. Arthritis Rheum. 1999, 42: 1285-1290. 10.1002/1529-0131(199906)42:6<1285::AID-ANR28>3.0.CO;2-1.CrossRefPubMed
21.
Fujita Y, Fujii T, Nakashima R, Tanaka M, Mimori T: Aseptic meningitis in mixed connective tissue disease: Cytokine and anti-U1RNP antibodies in cerebrospinal fluids from two different cases. Mod Rheumatol. 2008, 18: 184-188. 10.1007/s10165-008-0022-7.CrossRefPubMed
22.
Nagai Y, Ishikawa O, Miyachi Y: Pneumomediastinum and subcutaneous emphysema associated with fatal interstitial pneumonia in dermatomyositis. J Dermatol. 1997, 24: 482-484.CrossRefPubMed
23.
Tanaka F, Origuchi T, Migita K, Tominaga M, Kawakami A, Kawabe Y, Eguchi K: Successful combined therapy of cyclophosphamide and cyclosporine for acute exacerbated interstitial pneumonia associated with dermatomyositis. Intern Med. 2000, 39: 428-430. 10.2169/internalmedicine.39.428.CrossRefPubMed
24.
Mok CC, To CH, Szeto ML: Successful treatment of dermatomyositis-related rapidly progressive interstitial pneumonitis with sequential oral cyclophosphamide and azathioprine. Scand J Rheumatol. 2003, 32: 181-183. 10.1080/03009740310002542.CrossRefPubMed
25.
Kameda H, Nagasawa H, Ogawa H, Sekiguchi N, Takei H, Tokuhira M, Amano K, Takeuchi T: Combination therapy with corticosteroids, cyclosporin A, and intravenous pulse cyclophosphamide for acute/subacute interstitial pneumonia in patients with dermatomyositis. J Rheumatol. 2005, 32: 1719-1726.PubMed
26.
Sato S, Hoshino K, Satoh T, Fujita T, Kawakami Y, Fujita T, Kuwana M: RNA helicase encoded by melanoma differentiation-associated gene 5 is a major autoantigen in patients with clinically amyopathic dermatomyositis: Association with rapidly progressive interstitial lung disease. Arthritis Rheum. 2009, 60: 2193-2200. 10.1002/art.24621.CrossRefPubMed
27.
Rozelle A, Trieu S, Chung L: Malignancy in the setting of the anti-synthetase syndrome. J Clin Rheumatol. 2008, 14: 285-288. 10.1097/RHU.0b013e31817d116f.CrossRefPubMed
28.
Legault D, McDermott J, Crous-Tsanaclis AM, Boire G: Cancer-associated myositis in the presence of anti-Jo1 autoantibodies and the antisynthetase syndrome. J Rheumatol. 2008, 35: 169-171.PubMed
29.
Targoff IN, Trieu EP, Levy-Neto M, Prasertsuntarasai T, Miller FW: Autoantibodies to transcriptional intermediary factor 1-gamma (TIF-g) in dermatomyositis. Arthritis Rheum. 2006, 54: s518-10.1002/art.22164.CrossRef
30.
Hoshino K, Muro Y, Sugiura K, Tomita Y, Nakashima R, Mimori T: Anti-MDA5 and anti-TIF1-{gamma} antibodies have clinical significance for patients with dermatomyositis. Rheumatology (Oxford). 2010, 49: 1726-1733. 10.1093/rheumatology/keq153.CrossRef
Metadata
Title
Myositis autoantibodies in Korean patients with inflammatory myositis: Anti-140-kDa polypeptide antibody is primarily associated with rapidly progressive interstitial lung disease independent of clinically amyopathic dermatomyositis
Authors
Eun Ha Kang
Ran Nakashima
Tsuneyo Mimori
Jinhyun Kim
Yun Jong Lee
Eun Bong Lee
Yeong Wook Song
Publication date
01-12-2010
Publisher
BioMed Central
Published in
BMC Musculoskeletal Disorders / Issue 1/2010
Electronic ISSN: 1471-2474
DOI
https://doi.org/10.1186/1471-2474-11-223

Other articles of this Issue 1/2010

BMC Musculoskeletal Disorders 1/2010 Go to the issue

Research article

Pelvic girdle pain - associations between risk factors in early pregnancy and disability or pain intensity in late pregnancy: a prospective cohort study

Research article

Women's experiences of sexual health when living with Rheumatoid Arthritis - an explorative qualitative study

Research article

The chondrogenic response to exercise in the proximal femur of normal and mdx mice

Research article

Self-reported cold sensitivity in normal subjects and in patients with traumatic hand injuries or hand-arm vibration syndrome

Research article

A retrospective comparative study of mortality and causes of death among patients with metal-on-metal and metal-on-polyethylene total hip prostheses in primary osteoarthritis after a long-term follow-up

Research article

Analysis of meniscal degeneration and meniscal gene expression